Novo’s Obesity Pipeline Keeps Evolving With up to $1B Lexicon Deal

By /

Lexicon’s LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down gastric emptying.

Scroll to Top